

- 17		1 an 1-12 a					of Medicine NLM			
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Во	
Search P	ubMed	for			***************************************		Go	Clear		
1		Limits	Preview/Index		History	Clipboard		Deta	ils	
About Entrez	Z	Display Abstr	act	Shov	v: 20 Sort	i	Send to	Text	1	
Text Version										

E-Utilities

☐ 1: Clin Pharmacol Ther. 1998 Apr;63(4):397-402.

Related Articles, Links

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Comment in:

• Clin Pharmacol Ther. 2000 Jun; 67(6):690.


Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.

Kantola T, Kivisto KT, Neuvonen PJ.

Department of Clinical Pharmacology, University of Helsinki, Finland.

BACKGROUND: Grapefruit juice increases the bioavailability of several drugs known to be metabolized by CYP3A4. We wanted to investigate a possible interaction of grapefruit juice with lovastatin, a cholesterollowering agent that is partially metabolized by CY P3A4. METHODS: An open, randomized, two-phase crossover study with an interval of 2 weeks between the phases was carried out. Ten healthy volunteers took either 200 ml double-strength grapefruit juice or water orally three times a day for 2 days. On day 3, each subject ingested 80 mg lovastatin with either 200 ml grapefruit juice or water, and an additional dose of 200 ml was ingested 1/2 and 1 1/2 hours after lovastatin intake. Serum concentrations of lovastatin and lovastatin acid were measured up to 12 hours. RESULTS: Grapefruit juice greatly increased the serum concentrations of both lovastatin and lovastatin acid. The mean peak serum concentration (Cmax) of lovastatin was increased about 12-fold (range, 5.2-fold to 19.7-fold; p < 0.001) and the area under the concentration-time curve [AUC(0-12)] was increased 15-fold (range, 5.7-fold to 26.3-fold; p < 0.001) by grapefruit juice. The mean Cmax and AUC(0-12) of lovastatin acid were increased about fourfold (range, 1.8fold to 11.5-fold; p < 0.001) and fivefold (range, 2.4-fold to 23.3-fold; p < 0.001) by grapefruit juice, respectively. The half-lives of lovastatin and lovastatin acid remained unchanged. CONCLUSIONS: Grapefruit juice can greatly increase serum concentrations of lovastatin and its active metabolite, lovastatin acid, probably by preventing CYP3A4-mediated first-pass metabolism in the small intestine. The concomitant use of grapefruit juice with lovastatin and simvastatin should be avoided, or the dose of these 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitors should be reduced accordingly.

Publication Types:



Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy

E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA.

Squibb Institute for Medical Research, Princeton, NJ 08543-4000.

The oral bioavailability of two HMG-CoA reductase inhibitors, pravastatin and lovastatin, was investigated in this randomized, two-way crossover study. Twenty healthy men were randomly assigned to treatment with a 40mg dose of pravastatin or lovastatin once daily for 1 week; steady state kinetics were assessed after the last dose. After 1 week of washout, each subject received the alternate treatment. Serum specimens were assayed by gas chromatography/mass spectrometry (GC/MS) for intact pravastatin or lovastatin acid and by bioassay for active inhibitor concentration and, after hydrolysis of lactones, for total inhibitor concentration. The systemic bioavailabilities of total (active plus potentially active) inhibitors for the two drugs were different, with the mean AUC value for lovastatin being 50% higher than that of pravastatin (mean +/- SEM AUC0-24 values of 285 +/-25 and 189 +/- 13 ng-equiv x hr/mL, respectively, P less than .0001). Pravastatin, which is administered as the monosodium salt, is present in the systemic circulation as the open acid; lovastatin, which is administered as the lactone, is present as both open-acid active metabolites (62%) and closed-ring lactone metabolites (38%), which are potentially active. Based on mean AUC values, pravastatin accounted for 75% of the active inhibitors from a pravastatin dose. Lovastatin acid accounted for just 25% of the active inhibitors from a lovastatin dose, with the remainder due to other active metabolites. Significant decreases from baseline in total and low-density lipoprotein (LDL) cholesterol were observed during the first treatment leg for both pravastatin and lovastatin (ABSTRACT TRUNCATED AT 250 WORDS)


Publication Types:

- Clinical Trial
- Randomized Controlled Trial

PMID: 2125605 [PubMed - indexed for MEDLINE]







	LUNAMEA				of Medicine N.M.			
Entrez PubMed	Nucleotid		Genome	Structure	OMIM	PMC	Journals	Во
Search PubMed	for lovastatin + lovastatin + acid + AUC Go Clear							
Douton L	Lim	its Pre	/iew/Index	History	Clip	board	De	etails
About Entrez	Display	Summary	Sho	w: 20 Sor		Send to	Text	of 2
Text Version		Items 21-23	Previous Page 2 of 2					
Entrez PubMed Overview	<u>St</u>	an HY, Triscari J wanson BN, Will harmacokineti	ard DA.				ed Articles, MG-CoA	
Help FAQ Tutorial New/Noteworthy E-Utilities	re B: P:	eductase inhib r J Clin Pharmac MID: 1907839 [l	itors pravasta ol. 1991 Jun;31 PubMed - index	itin and lovas (6):665-70. ed for MEDLIN	tatın. E]			
PubMed Services Journals Database	В	an HY, DeVault N, Sugerman A	1 .				ted Articles	
MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby	☐ 10 J P	Comparative povastatin. Clin Pharmacol. MID: 2125605	1990 Dec;30(1 PubMed - index	2):1128-35. xed for MEDLIN	Œ]			
,	□ 23: V	ickers S, Dunca	n CA, Chen IW	<u>, Rosegay A, Dı</u>	iggan DE.	Rela	ted Articles	, Links
Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central		Metabolic disp prodrug. Drug Metab Disp PMID: 1971563 Items 21-2	osition studi os. 1990 Mar-A PubMed - inde	es on simvasta .pr;18(2):138-45	atin, a cho	lesterol-	lowering	of 2

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Aug 30 2004 06:52:01